Apogee Therapeutics (APGE) grants CMO 83,690 stock options

Rhea-AI Filing Summary

Apogee Therapeutics Chief Medical Officer Carl Dambkowski received a new stock option grant. On January 2, 2026, he was awarded an option to purchase 83,690 shares of Apogee Therapeutics common stock at an exercise price of $75.78 per share. The option was reported as held directly by the officer.

The option will vest in 48 equal monthly installments over four years from the grant date, as long as he continues providing service to the company. The option expires on January 2, 2036, and represents a long-term equity incentive rather than an immediate share purchase.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dambkowski Carl

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$75.78	01/02/2026		A		83,690		(1)	01/02/2036	Common Stock	83,690	$0.00	83,690	D

Explanation of Responses:

1. This option represents the right to purchase 83,690 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Apogee Therapeutics (APGE) report for its CMO?

Apogee Therapeutics reported that Chief Medical Officer Carl Dambkowski received a grant of stock options on January 2, 2026, giving him the right to buy 83,690 shares of the company’s common stock.

What is the exercise price of the CMO stock options at Apogee Therapeutics (APGE)?

The granted stock option allows the purchase of Apogee Therapeutics common stock at an exercise price of $75.78 per share.

How do the 83,690 Apogee Therapeutics (APGE) CMO stock options vest?

The option to buy 83,690 shares will vest in 48 equal monthly installments over a four-year period starting from the January 2, 2026 grant date, conditioned on the CMO’s continued service.

When do the Apogee Therapeutics (APGE) CMO stock options expire?

The stock option granted to the Chief Medical Officer is scheduled to expire on January 2, 2036, if not exercised earlier.

Is the Apogee Therapeutics (APGE) CMO option grant reported as directly owned?

Yes. The Form 4 shows the 83,690 stock options as directly owned (D) by Chief Medical Officer Carl Dambkowski, with no indirect ownership entity noted.

Does the Apogee Therapeutics (APGE) CMO pay cash to receive these options?

The Form 4 reports a $0.00 price for the option grant itself, which is typical for equity compensation; any cash payment would occur only if and when shares are purchased at the $75.78 exercise price.